Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: HBM9161
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: BlackRock Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 17, 2020
Net proceeds to be used in development of company's three anchor products: Batoclimab, tanfanercept, and HBM4003, to fund ongoing and planned clinical trials, and potential commercialization of other drug candidates in the Company’s pipeline.
Lead Product(s): Leniolisib
Therapeutic Area: Immunology Product Name: CDZ173
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Leniolisib is a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor with immunomodulating and potentially anti-neoplastic activities. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate (PIP3).